Ethics, pharmacy, policy and pediatric cancer experts publish recommendations for managing and preventing drug shortages
A group of prominent healthcare experts including bioethicists, pharmacists, policymakers and cancer specialists have proposed concrete steps for preventing and managing a nightmare scenario that is becoming all too common: shortages of life-saving drugs.
In a consensus statement published in the journal Pediatrics, the experts say they sought to move away from the current strategy of reaction to shortages once they have occurred and focus instead on prevention. Using the example of shortages of chemotherapy drugs used for treating children with cancer—therapies proven to have high survival rates for the most common childhood cancers—the group developed “a comprehensive blueprint for action” they say is critical for managing and preventing future drug shortages.
“Although our recommendations were developed with pediatric oncology in mind, and serve as a blueprint for preventing children with cancer from lacking access to essential life-saving medications, we believe that they apply more broadly across medicine to include pediatrics and adult medicine in general,” says Yoram Unguru, a pediatric hematologist/oncologist at the Herman and Walter Samuelson Children’s Hospital at Sinai and faculty member at the Johns Hopkins Berman Institute of Bioethics. Unguru, a coauthor of the consensus statement, was the principal organizer of meetings that led to its creation, bringing together representatives from the Food and Drug Administration (FDA), leadership of the Children’s Oncology Group and The American Society of Pediatric Hematology/Oncology, patient advocacy groups, legal scholars and clinicians.
Some recommendations would represent new norms for healthcare practice, including the sharing of scarce drugs between healthcare institutions and not giving preferential access to patients participating in research studies.
“This statement is significant both for the consensus found by such a diverse group of experts, and for being the first to take seriously the ethical rationale to prevent shortages in the first place,” says Matthew DeCamp, a Johns Hopkins professor at the Berman Institute of Bioethics and Division of General Internal Medicine, and lead author of the consensus statement.
Included in the statement’s six recommendations is a call to develop policies that give equal priority to patients regardless of whether they are participants in research. The authors acknowledge this “may be controversial,” due to the sentiment that fairness requires giving research participants high-priority access to drugs because of their contribution to medical knowledge and future patients. However, the statement’s authors explain that “concerns over undue inducement, public perception, and the imperative to use drugs for indications for which evidence of benefit exists outweigh arguments for giving priority access to research participants.”
For each recommendation the statement also includes potential barriers to its implementation. A centralized information source of drug supply information, for instance, faces the risk that such information will encourage hoarding of existing supplies, including so-called “gray market” suppliers that sell scarce drugs for inflated prices. The statement calls for new policies for both reporting and avoiding these markets, though acknowledges the temptation of healthcare providers to use them in a shortage, when their patients are in need.
The Latest on: Shortages of life-saving drugs
via Google News
The Latest on: Shortages of life-saving drugs
- New challenge for kids with cancer: thieves steal their medicationson October 12, 2020 at 1:53 pm
Mexico has long been plagued by a shortage of medications for children with cancer. Now the problem has been exacerbated by thieves.
- Hospitals Need to Be Able to Repair Their Own Medical Equipmenton October 12, 2020 at 7:09 am
Sen. Ron Wyden and biomedical engineer Ilir Kullolli on why Congress must pass the Critical Medical Infrastructure Right-to-Repair Act.
- Pakistan facing shortage of hepatitis, influenza, other vaccineson October 10, 2020 at 4:39 am
The country is facing a shortage of many vaccines including hepatitis, influenza and various other medicines as the drugs have vanished from markets.
- Sudan: Covid-19, Chikungunya On the Rise in Sudan As Drug Supplies Dwindleon October 8, 2020 at 10:57 am
The Sudanese Ministry of Health announced the registration of 15 new COVID-19 cases during the period from October 1-5, while the number of samples examined during the reporting period reached 5,096.
- Flintshire police carrying life-saving nasal spray for drug overdoses 'right move', according to ex-useron October 8, 2020 at 8:43 am
A pilot scheme has been established in Flintshire where some police officers will carry Naloxone nasal sprays. The spray acts as an antidote to drug overdoses.
- Medical supply chain shortages led to deadly consequenceson October 6, 2020 at 8:17 am
Despite decades of warnings about the fragility of the supply lines that brought protective gear from overseas factories to America’s health care workers, the U.S. was unprepared for the coronavirus ...
- Take approriate measures to curb black marketing of life-saving drugs in Maha: JB Mantrion October 5, 2020 at 10:06 am
Remdesivir injection is a drug approved by the government for Covid patients. At present, there are adequate stocks of this medicine in Maharashtra and there is no shortage. However, authorities have ...
- Trump’s Covid Treatment and What the Options Areon October 2, 2020 at 2:53 pm
The scramble to develop treatments for Covid-19 has paid off. A number of therapies are improving the chances of survival for very sick patients. Since the disease first emerged, medical professionals ...
- Drug prices hike compelling many to quit treatmenton October 1, 2020 at 7:43 pm
Up to 260 per cent increase in prices of medicines has compelled a major segment of patients to reduce drug dosage or discontinue treatment, while leading pharmaceutical manufactures believe the move ...
- Let's Not Europeanize American Pharmaceuticalson September 30, 2020 at 8:36 am
I criticized Nancy Pelosi’s scheme to impose European-style price controls on pharmaceutical drugs in the United States.I wasn’t the only one who objected to Pelosi’s reckless idea.We have forty centu ...
via Bing News